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ABSTRACT
Background: Hypersensitivity pneumonitis (HP) is an immune-mediated lung disease induced by inhalation
of numerous antigens. Pathologically, chronic HP tends to show usual interstitial pneumonia (UIP) and fibrotic
nonspecific interstitial pneumonia (fNSIP) patterns. Patients with UIP pattern present insidious onset and a risk
for acute exacerbations.
Methods: To evaluate the proteomic differences of bronchoalveolar lavage fluid (BALF) between UIP and
fNSIP patterns, BALF from seven patients with UIP pattern and four patients with fNSIP pattern was examined
using two-dimensional gel electrophoresis and mass spectrometry.
Results: By individually comparing each BALF sample, we found that the protein levels of surfactant protein A
(SP-A), immunoglobulin heavy chain α, α-2 heat shock glycoprotein, haptoglobin β, and immunoglobulin J
chain were significantly higher in the patients with UIP pattern than those in the patients with fNSIP pattern. In
contrast, the protein levels of glutathione s-transferase, vitamin D-binding protein, and β-actin were significantly
higher in the patients with fNSIP pattern than those in the patients with UIP pattern. To confirm the results of
SP-A in the BALF proteome, we performed enzyme-linked immunosorbent assay in a larger group. The con-
centrations of SP-A in BALF from the patients with UIP pattern were significantly higher than those from the pa-
tients with fNSIP pattern (2.331 ± 1.656 μgml vs. 1.319 ± 1.916 μgml, p = 0.034).
Conclusions: We identified several proteins that may play roles in the development of pathological differ-
ences between UIP and fNSIP patterns of chronic HP.
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INTRODUCTION
Hypersensitivity pneumonitis (HP) is an immune-
mediated lung disease induced by inhalation of anti-
gens present in a wide variety of organic dusts. HP is
classified into acute and chronic forms based on its
clinical presentation.1,2 Moreover, chronic HP is sub-
grouped into recurrent and insidious types.3 The re-
current type is the subgroup of chronic HP patients
presenting recurrent acute episodes, including low-
grade fever. The insidious type is the subgroup of
chronic HP patients with a slowly progressive course
without acute episodes. Chronic HP is induced by
persistent exposure to a small quantity of antigen. Pa-
tients with chronic HP often develop pulmonary fibro-
sis with the destruction of lung parenchyma, and the
prognosis is poor. This clinical course is similar to
that of idiopathic pulmonary fibrosis (IPF). However,
the pathogenesis of fibrogenesis in chronic HP re-
mains unclear.
In chronic HP, surgical lung specimens exhibit
various histological patterns, including UIP pattern,
fNSIP pattern, cellular nonspecific interstitial pneu-
monia (cNSIP) pattern, and organizing pneumonia
(OP) pattern,4 as observed in IIPs.5 We have showed
five clinical differences between UIP and fNSIP pat-
terns in the previous reports.3,4 First of all, all cases
with UIP pattern were insidious type of chronic HP
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and half cases with fNSIP pattern were recurrent
type.6 Second, the percentage of lymphocytes in
BALF with UIP pattern tended to be lower than that
with fNSIP pattern (p = 0.052).4 Third, in histology,
giant cells or granulomas were observed in lung
specimens from all of the fNSIP cases, whereas no
granuloma was shown in the UIP cases. Fourth, the
prognosis of fNSIP pattern tended to be better than
that of UIP pattern (p = 0.065, median survival; 29
months vs. 63 months). Finally, the patients with UIP
pattern at the time of diagnosis may be at higher risk
for acute exacerbations (AE) than those with fNSIP
or cNSIP patterns.7 These lines of evidence suggest
that comparative BALF analysis might provide some
information of the pathogenesis in UIP and fNSIP pat-
terns.
Proteomic analysis of human body fluids has be-
come an important approach for the discovery of
biomarkers. The analysis of the BALF proteome can
potentially provide important information of differ-
ences or changes in protein expression and secretion
during the course of pulmonary disorders. Previous
studies have shown that the protein composition of
BALF is altered in sarcoidosis,8 IPF,9 pulmonary al-
veolar proteinosis,10,11 cystic fibrosis,12 chronic ob-
structive pulmonary disease,13 systemic sclerosis
with pulmonary fibrosis,14 and HP.8 BALF has been
widely used to collect cells and other soluble compo-
nents from epithelial lining fluids that cover the air-
way and the alveoli.15 BALF contains proteins se-
creted from various cell types, including epithelial
and inflammatory cells as well as a wide variety of
proteins from the bloodstream. Therefore, the analy-
sis of BALF may reveal important biological activities
related to inflammation, oxidation-reduction, tissue
matrix turnover, and immunity.
The aim of our study was to investigate the differ-
ences in the BALF proteome of patients with UIP and
fNSIP patterns of chronic HP.
METHODS
PATIENT SELECTION
BALF samples were obtained from patients with
chronic HP who underwent surgical lung biopsies in
our hospital between 1998 and 2008. The diagnosis of
chronic HP was based on clinical, radiological, and
histological criteria, as described previously.4 Out of
11 chronic HP patients, seven patients with UIP pat-
tern and four patients with fNSIP pattern were en-
rolled in this study. Patients with UIP and fNSIP pat-
terns were compared with smoking habits, laboratory
test, including serum levels of C-reactive protein
(CRP), LDH, Krebs von den Lungen 6 (KL-6), and
surfactant protein D (SP-D), and pulmonary function
test including predicted vital capacity percentage
(%VC), percentage of forced expiratory volume in one
second (%FEV1.0), percentage of diffusing capacity for
carbon monoxide (%DLco), and percentage of diffus-
ing capacity for carbon monoxide corrected for alveo-
lar volume (%DLcoVA). Patients were provided in-
formed consent for bronchoscopy, and none of them
were treated with prednisolone or other immunosup-
pressive agents at the time of enrollment. The study
conformed to the Declaration of Helsinki and was ap-
proved by the internal review boards of our institu-
tion.
BRONCHOALVEOLAR LAVAGE (BAL)
We performed BAL using three 50-ml aliquots of ster-
ile 0.9% saline, as previously described.16 The cellular
composition of the BALF was determined by count-
ing 200 cells in a cytospun smear with Wright’s stain.
The analysis of lymphocyte phenotypes was per-
formed by flow cytometry, using monoclonal antibod-
ies for CD4 and CD8.
PATHOLOGICAL ASSESSMENT
Histological patterns were evaluated by two pulmo-
nary pathology specialists (T.T. and T.A.) without the
knowledge of the patient’s clinical course. The pa-
tients were subgrouped into UIP, fNSIP, and cNSIP
OP patterns according to the international classifica-
tion of idiopathic interstitial pneumonias proposed by
the joint ATSERS statement in 2002.4 When the
opinions differed between the two pathologists, the fi-
nal decision was reached by consensus.
TWO-DIMENSIONAL GEL ELECTROPHORESIS
Two-dimensional gel electrophoresis (2-DE) was per-
formed as previously described.17 Briefly, BALF sam-
ples were freeze-dried and concentrated by acetone
precipitation. In each analytical experiment, the same
amount of samples (54 μl) were loaded on immobi-
lized pH gradient (IPG) strips (pH 3 to 10, 18 cm; GE
healthcare, Uppsala, Sweden) concentrated by ace-
tone and swollen in 8 M urea, 4% CHAPS, 65 mM
dithioerythritol, 0.1 M acetic acid, pharmalyte (pH 3
to 10 for isoelectrofocusing; GE healthcare), and a
trace of bromophenol blue. Rehydration was per-
formed in the strip holder of the IPG-IEF Cool-
PhoreStar system (Anatech, Tokyo, Japan) at 20℃
and isoelectrofocusing was terminated at 47 kV. The
IPG strips were equilibrated first in the ureaSDS
Tris buffer for 30 minutes and then in the same buffer
containing 2.5% iodoacetamide. The second-
dimensional run was performed on 10% poly-
acrylamide linear gradient gels, with a constant cur-
rent of 20 to 30 mAgel at 20℃, until the dye front
reached the bottom of the gels. The gels were stained
with SYPRO Ruby Protein Gel Stain (Molecular
Probes, Carlsbad, CA, USA).
EVALUATION AND IDENTIFICATION OF PRO-
TEINS
The gels were scanned using FluoroPhoreStar 3000
(Anatech), analyzed using Progenesis PG220 Soft-
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Table　1　Patients characteristics
UIP fNSIP p value
Number 7 4 -
Gender (M/F) 7/0 3/1 -
Age (yr)   58.9 ± 7.5   57.5 ± 11.3 0.925
Smoking history (pack-year)   40.2 ± 24.7   45.1 ± 37.6 0.927
Serum CRP (mg/dl)    0.2 ± 0.2    0.7 ± 0.8 0.774
Serum LDH (IU/l)  265.1 ± 69.1  262.0 ± 70.7 0.527
Serum KL-6 (U/ml) 2249.6 ± 1147.4 1062.0 ± 508.6 0.109
Serum SP-D (ng/ml)  293.3 ± 249.9  192.8 ± 171.7 0.527
%VC (%)   85.2 ± 22.8   86.8 ± 12.0 0.927
%FEV1.0 (%)   77.3 ± 17.5   78.0 ± 8.9 0.649
%DLco (%)   57.7 ± 12.5   54.8 ± 7.1 0.788
%DLco/VA (%)   77.5 ± 18.4   65.6 ± 28.7 0.412
Results were shown as number or mean ± SD.
Abbreviations: UIP, usual interstitial pneumonia; fNSIP, fi brotic nonspecifi c interstitial pneumonia; KL-6, Krebs von den Lungen 6; SP-D, 
pulmonary surfactant protein D; %VC, percentage of volume capacity; %FEV1.0, percentage of forced expiratory volume in one second; 
%DLco, percentage of diffusing capacity for carbon monoxide; %DLco/VA, percentage of diffusing capacity for carbon monoxide corrected 
for alveolar volume.
ware (Nonlinear Dynamics Ltd, Newcastle upon
Tyne, UK), and automatically analyzed using the spot
detection feature of the software, with automatic
warping and matching. Spot volumes were corrected
for background using the “mode of non-spot” method
and were normalized. A normalization spot volume
was an area and a density achieved using spot vol-
umes multiplied by total area, when the total spot vol-
ume was defined as 100. The normalized spot vol-
umes were used for comparison among different
clinical groups. Proteins were identified by compar-
ing the BALF maps, such as the SWISS-2D PAGE hu-
man plasma map and published BALF maps,14,18 or
by liquid chromatography nano electron spray ioniza-
tion tandem mass spectrometry (LC-nESI-MSMS)
(QTRAP 5500 LCMSMS System, AB SCIEX, Con-
cord, ON, Canada). The protein spots of interest
picked up from the gels were analyzed by LC-nESI-
MSMS in the Laboratory of Cytometry and Pro-
teome Research, Tokyo Medical and Dental Univer-
sity. LC separation was performed on a HiQ sil C18W-
3P column (0.1 mmΦ × 100 mm, KYA TECH Corpo-
ration, Tokyo, Japan). Elution was performed at a
flow rate of 300 nLmin, using water containing 0.1%
(vv) formic acid as the eluent A and acetonitrile con-
taining 0.1% (vv) formic acid as the eluent B with a
linear gradient from 5% B to 45% B in 70 minutes.
Data analysis was performed using ProteinPilotTM
software (Version 3, Applied Biosystems, Warring-
ton, UK).
ENZYME-LINKED IMMUNOSORBENT ASSAY
(ELISA)
Since surfactant protein A (SP-A) and glutathione s-
transferase pi (GST-pi) could be evaluated by ELISA,
we measured serum and BALF SP-A and GST-pi in a
larger group to confirm the result of SP-A in the
BALF proteome. Using an ELISA kit (BioVendor-
Laboratorni medicina a.s., Brno, Czech Republic), we
measured the SP-A concentration of serum in 42 pa-
tients, including 25 patients with UIP pattern and 17
patients with fNSIP pattern, and that of BALF (diluted
to 1 : 200) in 24 patients, including 15 patients with
UIP pattern and 9 patients with fNSIP pattern. The
sensitivity of this assay was to detect SP-A from 1 to
50 ngml. We measured the GST-pi concentration of
serum and BALF in the same population using an
ELISA kit (Immundiagnostik AG, Bensheim, Ger-
many). The sensitivity of this assay was to detect
GST-pi from 9.4 to 600 ngml.
STATISTICAL METHODS
Data were analyzed using Prism 5 (GraphPad Soft-
ware, Inc., San Diego, CA, USA) and were described
as the mean ± standard deviation (SD). The two
groups were compared using the Mann-Whitney U
test. Correlation coefficient was obtained using the
Spearman’s correlation coefficient test. All statistical
comparisons were two-sided, and p values < 0.05 were
considered statistically significant.
RESULTS
Proteome analysis of individual BALF samples was
performed on 11 patients with chronic HP, including
seven with UIP pattern and four with fNSIP pattern.
Patient characteristics and BALF findings are shown
in Table 1, 2. All of the patients with UIP pattern were
males, and the patients with fNSIP pattern included
three males and one female. All of the patients were
ex-smokers. The levels of KL-6 and SP-D were ele-
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Table　2　Bronchoalveolar lavage fl uid analysis
UIP fNSIP p value
Number 7 4 -
Recovery rate (%)  61.2 ± 16.8  50.4 ± 10.8 0.394
Total cell count (×105/ml)  3.53 ± 1.99  3.37 ± 1.89 1.000
Macrophage (%)  80.0 ± 10.3  71.0 ± 19.7 0.649
Neutrophils (%)   4.2 ± 6.9   4.5 ± 4.6 0.788
Eosinophils (%)   0.7 ± 0.5   5.2 ± 4.1 0.010
Lymphocytes (%)  15.2 ± 9.1  19.4 ± 18.8 0.924
CD4+/CD8+ ratio   3.4 ± 2.7   1.9 ± 0.8 0.256
Protein concentration (μg/ml) 261.7 ± 70.0 249.8 ± 59.8 0.927
Results were shown as mean ± SD.
Abbreviations: UIP, usual interstitial pneumonia; fNSIP, fi brotic nonspecifi c interstitial pneumonia.
Fig.　1　Two-Dimensional Electrophoresis (2-DE) of BALF
from a chronic HP patient with UIP pattern (a), performed us-
ing a nonlinear immunobiline gradient 4-7, IPG strip followed 
by 10% SDS PAGE. Proteins were detected by SYPRO-Ru-
by. Numbers indicate proteins and are listed in Table 3. Rep-
resentative 2-DE patterns of BALF from UIP pattern (b) and
fNSIP pattern (c).
vated, and the diffusing capacity of the patients,
shown by the pulmonary function test, was reduced
in both groups. The KL-6 level in the patients with
UIP pattern tended to be higher than that in those
with fNSIP pattern. In their BALF profiles, the per-
centage of eosinophils was significantly higher in the
patients with fNSIP pattern than that in those with
UIP pattern. The percentages of lymphocytes were
elevated in both groups, and no difference was ob-
served between the two groups. Other clinical charac-
teristics were similar between the two groups. No mi-
crobiological or clinical evidence of bacterial or fun-
gal infection was found in any patient.
We analyzed the BALF proteome in the patients
with UIP and fNSIP patterns by 2-DE to evaluate the
difference in protein expression between the two
groups. The 2-DE patterns of BALF are shown in Fig-
ure 1. The total number of spots was significantly
higher in BALF from the patients with UIP pattern
than that from those with fNSIP pattern (550 ± 109.3
spots vs. 410 ± 69 spots, p = 0.042; Fig. 1b, c). We
identified 41 species of proteins using LC-nESI-MS
MS andor gel matching (GM) with the 2-DE data-
base from Swiss-PROT (Fig. 1b, c; Table 3). By indi-
vidually comparing the BALF samples, we found that
the levels of SP-A, immunoglobulin heavy chain α, 60-
kDa α-2 heat shock glycoprotein (HSP60), haptoglo-
bin β, and immunoglobulin J chain were significantly
higher in the patients with UIP pattern than those in
the patients with fNSIP pattern (Table 4). In contrast,
the levels of GST-pi, vitamin D-binding protein
(VDBP), and β-actin were significantly higher in the
patients with fNSIP pattern than those in the patients
with UIP pattern (Table 5). SP-A was shown as nine
spots, representing different isoforms, along a
downward-sloping line (Fig. 2). These isoforms were
likely to be categorized into two types of spots (num-
ber 1, 2, 4, 6, 8, and 9 were vertically long, whereas
number 3, 5, and 7 were obliquely long). The quantity
of number 5 spot in UIP pattern was significantly
higher than that in fNSIP pattern, although the other
eight spots showed no difference between UIP and
fNSIP patterns.
The concentrations of SP-A in serum and BALF
were determined by ELISA (Fig. 3). The level of SP-A
in BALF from the patients with UIP pattern was sig-
nificantly higher than that in those with fNSIP pattern
(2.331 ± 1.656 μgml vs. 1.319 ± 1.916 μgml, p =
Proteome Analysis of BALF in Chronic HP
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Table　3　BALF proteins identifi ed in UIP and fNSIP patients
Protein No. Protein AC Identifi cation method
1 α-2 macroglobulin P-01023 GM
2 Ceruloplasmin P-00450 GM, MS
3 Immunoglobulin A-S chain P-99003 GM, MS
4 Complement factor B P-00751 GM
5 α-1 B-glycoprotein P-04217 GM, MS
6 Hemopexin P-02790 GM, MS
7 Albumin P-02768 GM, MS
8 Transferin P-02787 GM, MS
9 Complement C3β P-01024 GM
10 Immunoglobulin heavy chain α P-99002 GM, MS
11 α-2 antiplasmin P-08697 GM, MS
12 α-1 antichymotrypsin P-01011 GM, MS
13 α-2-HS-glycoprotein P-02765 GM, MS
14 Antithrombin III P-01008 GM, MS
15 Vitamin D-binding protein P-02774 GM, MS
16 α-1 antitrypsin P-01009 GM, MS
17 Zinc fi nger protein GLIS1 P-08151 MS
18 Apolipoprotein A-IV P-06727 GM
19 β-actin P-60709 GM, MS
20 Fibrinogen γ, α chain P-02679 GM
21 Immunoglobulin heavy chain μ P-99009 GM, MS
22 Immunoglobulin heavy chain γ P-99006 GM
23 Zinc α-2-glycoprotein P-25311 GM
24 Haptoglobin β P-00737 GM, MS
25 Toll-like receptor 1 P-38593 MS
26 Orosomucoid 1 P-02763 GM
27 Pulmonary surfactant protein A P-07714 GM, MS
28 Immunoglobulin J chain P-01591 GM, MS
29 Complement factor I P-05156 GM
30 C-reactive protein P-02741 GM
31 Proapolipoprotein AI P-39133 GM
32 Immunoglobulin light chain κ, λ P-99007 GM
33 Apolipoprotein A-1 P-02647 GM
34 Glutathione S-transferase pi P-09211 GM, MS
35 Translationally controlled tumor protein P-13693 GM
36 Serum retinol binding protein P-02753 GM
37 Haptoglobin α P-00738 GM
38 Superoxide dismutase (Cu-Zn) P-00441 GM
39 Transthyretin P-02766 GM, MS
40 Immunoglobulin binding factor P-15923 GM
41 Calgranulin B P-31725 GM
Protein No.: refer to the annotations in Fig. 1.
Abbreviations: AC, accession number from the SWISS-PROT database; MS, LC-nESI-MS/MS; GM, Gel matching with two dimensional 
gel electrophoresis database from SWISS-PROT.
0.034; Fig. 3b); however, the serum level of SP-A
showed no difference between the two groups (94 ±
38 ngml vs. 101 ± 53 ngml, p = 0.959; Fig. 3a). The
concentrations of GST-pi in serum and BALF showed
no difference between two groups (serum; 37.0 ± 34.2
ngml vs. 53.1 ± 61.6 ngml, p = 0.710, BALF; 17.8 ±
15.4 ngml vs. 12.2 ± 9.2 ngml, p = 0.551; Fig. 4).
There was no correlation between the serum level
and the BALF level of SP-A (p = 0.583, r = -0.124; Fig.
5a). In contrast, there was a significant negative cor-
relation between the SP-A level and the percentage of
eosinophils in BALF (p = 0.0009, r = -0.631; Fig. 5b),
whereas there was no correlation between the SP-A
level in BALF and other clinical parameters, includ-
Okamoto T et al.
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Table　4　Proteins of higher normalization volume in UIP pattern than fNSIP pattern
Protein MW (kDa)/pI Normalization volume of UIP (×10-3)
Normalization volume of 
fNSIP (×10-3) p value
60 kDa α2 heat shock glycoprotein 61.1/5.7   79.4 ± 60.1  17.8 ± 14.8 0.029
Haptoglobin β 45.2/6.1  438.6 ± 392.4  90.5 ± 97.2 0.012
Immunoglobulin heavy chain α 37.7/6.1  946.7 ± 502.8 126.5 ± 99.1 0.024
Surfactant protein A (isoforms number 5) 26.2/5.1 1153.3 ± 641.5 339.6 ± 285.5 0.024
Immunoglobulin J chain 18.1/5.1  243.6 ± 197.9  27.1 ± 53.9 0.029
Results were shown as mean ± SD.
Abbreviations: UIP, usual interstitial pneumonia; fNSIP, fi brotic nonspecifi c interstitial pneumonia.
Table　5　Proteins of higher normalization volume in fNSIP pattern than UIP pattern
Protein MW (kDa)/pI Normalization volume of UIP (×10-3)
Normalization volume of 
fNSIP (×10-3) p value
Vitamin D-binding protein 53.0/5.4 146.9 ± 81.8  375.3 ± 172.0 0.029
β-actin 42.0/5.9  36.0 ± 29.5  315.0 ± 194.3 0.024
Glutathione s-transferase pi 23.4/5.4  65.3 ± 29.1 189.6 ± 73.1 0.012
Results were shown as mean ± SD.
Abbreviations: UIP, usual interstitial pneumonia; fNSIP, fi brotic nonspecifi c interstitial pneumonia.
Fig.　2　The SP-A isoforms of UIP (a) and fNSIP (b) 
patterns. The normalization volume of number 5 in UIP pat-
tern was signifi cantly higher than that of fNSIP pattern.
Fig.　3　The concentrations of SP-A in serum (a) and BALF 
(b) in comparison between UIP and fNSIP patterns. Bars 
showed the median values. *p = 0.034.
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ing serum KL-6, SP-D, LDH, pulmonary function, the
percentages of lymphocytes and neutrophils, and the
ratio of CD4 to CD8.
DISCUSSION
This study is the first report of the protein expression
in BALF from patients with chronic HP, in which dif-
ferent histological patterns were analyzed using a
proteomic approach. We identified eight proteins
whose expression levels were significantly different
between the histological patterns of UIP and fNSIP.
Additionally, we found a number of SP-A isoforms dif-
fering in molecular weight and pH. Those proteins
and isoforms might be associated with the patho-
genesis of histological patterns of UIP and fNSIP.
In patient characteristics, there was no difference
between UIP and fNSIP patterns. In BALF profiles,
the percentage of eosinophils in fNSIP pattern was
significantly higher than that in UIP pattern. This re-
sult is consistent with our previous study, showing
that the group having an episode of AE in chronic HP
presented a lower percentage of eosinophils than the
group without an episode of AE, and that the patho-
logical type of almost all except one with AE was UIP
Proteome Analysis of BALF in Chronic HP
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Fig.　4　The concentrations of GST-pi in serum (a) and
BALF (b) in comparison between UIP and fNSIP patterns. 
Bars showed the median values.
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Fig.　5　Correlation relationship of the concentrations be-
tween serum SP-A and BALF SP-A (a), and correlation rela-
tionship between the percentage of eosinophils and the con-
centrations of SP-A in BALF (b).
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pattern.7 However, the relationship between eosino-
phils and AE was still unknown.
Moreover, we identified five proteins whose nor-
malization volume of UIP pattern was higher than
that of fNSIP pattern, including SP-A and HSP60. SP-
A is a hydrophilic calcium-dependent lectin, known as
collectin, which is primarily produced by the type II
alveolar epithelial cells in the lung and is secreted
into the lung alveolar space. Surfactant stabilizes the
gas-exchanging surface of the alveoli and plays a role
in pulmonary host defense by binding, aggregating
and opsonizing various microorganisms. SP-A also af-
fects the function of alveolar macrophages, other im-
mune cells, and lung fibroblasts. Some studies sug-
gested that SP-A is associated with the regulation of
matrix metalloproteinases, extracellular matrix com-
ponents, and potentially the repair and remodeling of
damaged tissue.19 However, controversial results on
the expression of SP-A in BALF samples of IPF pa-
tients have also been reported.20-22 By comparing the
gene expression profile between relatively stable IPF
and progressive IPF, a previous study reported that
SP-A was upregulated in the progressive group.23
Similar to their finding, in the present study, we ob-
served elevated protein expression of SP-A in the pa-
tients with UIP pattern. Regarding HP, previous stud-
ies have shown that the level of SP-A in BALF from
patients with HP is elevated, compared to that from
healthy volunteers.24 However, there has been no re-
port regarding the relative concentrations of SP-A in
BALF among a variety of histological patterns of HP.
In this study, the difference of SP-A between the two
groups may result from the synthesis andor release
of SP-A by secreting cells or from impaired clearance
by alveolar macrophages, mucociliary transport, deg-
radation, and absorption into the bloodstream. There-
fore, we suggest that the synthesis and release of SP-
A in UIP pattern may increase or that the clearance of
SP-A in UIP pattern may be impaired, compared to
that in fNSIP pattern. There was a significant nega-
tive correlation between the SP-A level and the per-
centage of eosinophils in BALF. Madan et al. showed
that knockout of SP-A gene induced the increase of
eosinophils in serum and BALF through IL-5 and
TNF-α in murine model.25 These data might support
that SP-A have a role in regulating the eosinophils in-
filtration and modification in the lung in response to
environmental stimuli.
In this study, 2-DE gel electrophoresis of BALF re-
vealed nine spots of SP-A. When the SP-A precursor
is processed into mature SP-A, it undergoes several
posttranslational modifications, including N-linked
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glycosylation, hydroxylation of proline residues, addi-
tion of sialic acid to the oligosaccharide, formation of
disulfide bonds, and signal peptide cleavage. These
posttranslational modifications may be important for
some SP-A functions. The heterogeneity of the mass
and charge of SP-A isoforms has been studied using
2-DE or mass spectrometry12,13; however, its molecu-
lar nature remains unclear. Posttranslational modifi-
cations of surfactant proteins were previously ana-
lyzed by matrix-assisted laser desorptionionization
high-solution Fourier transform ion cyclotron reso-
nance mass spectrometry (MALDI-FT-ICR MS) in
BALF from patients with cystic fibrosis.12 Ohlmeier et
al. identified nine isoforms of SP-A in lung tissue of
chronic obstructive pulmonary disease (COPD).13 In
the present study, we observed nine spots represent-
ing different SP-A isoforms and that these spots were
categorized into two types of shapes (number 1, 2, 4,
6, 8, and 9 were vertically long, whereas number 3, 5,
and 7 were obliquely long; Fig. 2). We considered
that the difference in shape may reflect the difference
in posttranslational modifications. The quantity of
number 5 spot in UIP pattern, shown in Figure 2 as a
SP-A isoform, was significantly higher than that in
fNSIP pattern, suggesting that the expression of num-
ber 5 spot might play an important role in the devel-
opment of pathologic differences between UIP and
fNSIP patterns.
HSP60 with a molecular mass of 60 kDa is mainly
expressed in mitochondria. The cellular protective
mechanisms of HSPs are related to their chaperone
functions, which lead to the prevention of protein de-
naturation and the promotion of the refolding of dam-
aged proteins caused by various stress, including oxi-
dative stress.26,27 HSP60 is also an antigen for the
adaptive immune system. T cells response to HSP60
epitopes, regulating inflammatory diseases, such as
rheumatoid arthritis, insulin-dependent diabetes mel-
litus, and atherosclerosis.28,29 Although there have
been no data regarding the induction of HSP60 in
chronic HP, the high level of BALF HSP60 in UIP pat-
tern suggested that HSP60 might be associated with
a defense response against lung inflammation or the
impairment of the immune system in chronic HP.
Additionally, we identified three proteins whose
normalization volume of UIP pattern was higher than
that of fNSIP pattern, including haptoglobin β, immu-
noglobulin heavy chain α, and immunoglobulin J
chain. Haptoglobin β, a part of haptoglobin, is an
acute phase protein in inflammation, tissue damage,
infection, and cancers. The expression level of hapto-
globin β is regulated by several cytokines, including
IL-1, IL-6, TNF-α, and TGF-β.30
Meanwhile, we identified three proteins whose nor-
malization volume of fNSIP pattern was higher than
that of UIP pattern, including VDBP and GST-pi.
VDBP belongs to the albumin superfamily of binding
proteins that includes albumin, α-albumin, and α-
fetoprotein. VDBP is expressed in many tissues, in-
cluding liver, kidney, gonads, and fat. It is also ex-
pressed by neutrophils, contributing to macrophage
activation,31 augmenting monocyte and neutrophil
chemotaxis to C5-derived peptides32 and serving as a
scavenger protein to clear extracellular G-actin re-
leased from necrotic cells.33 The low level of VDBP in
UIP pattern, which may reflect the impairment of its
role as a scavenger protein or of protection against in-
flammation, might contribute to the high susceptibil-
ity to pulmonary fibrosis and progressive clinical
course.
Oxidative stress is important for the pathogenesis
of lung damage and for the development of lung fibro-
sis. Among various enzymatic and non-enzymatic
mechanisms that protect cells and tissues from oxi-
dants, GSTs and SODs play a key protective role, es-
pecially in the lung.34 The lower level of GST-pi in
UIP pattern might induce continuous oxidative stress
to the lung. In the present study, we observed a lower
level of GST-pi in the patients with UIP pattern, sug-
gesting that the impairment of protection from oxida-
tive stress by GST-pi might play a critical role in the
pathogenesis of chronic HP and IPF. Recently, sev-
eral studies have reported the efficacy of N-
acetylcysteine as an antioxidant in the treatment of
IPF.35 Similarly, in chronic HP, GST could be a poten-
tial therapeutic target, and N-acetylcysteine might im-
prove the oxidant-antioxidant imbalance in clinical
settings. We could not find the difference of GST-pi
expression in serum and BALF by ELISA. This was
because ELISA and 2-DE might detect different
forms of GST-pi differently.
We found that SSc with pulmonary fibrosis showed
increased expression of three proteins, including α2-
macroglobulin, α1-antitrypsin, and SP-A, and de-
creased expression of two proteins, including HSP60
and GST-pi.17 We considered that the changes in SP-
A and GST-pi are not disease-specific because the
changes of these two proteins were very similar to
the results in the present study. In contrast, the al-
teration of HSP60 showed the opposite tendency be-
tween these two studies. In the present study, the
high level of HSP60 in BALF might be a consequence
of the defense response against lung inflammation or
of the impairment of immune system.
There were several limitations of this study. First,
it was not clear whether the alternations in protein
expression were systemic or local events in the lung.
Second, we were not able to investigate hydrophobic
proteins by the 2-DE technique. For example, surfac-
tant protein C, a hydrophobic protein critically in-
volved in surfactant homeostasis, was unable to be
analyzed by 2-DE. Third, the power to detect statisti-
cally differences between UIP and fNSIP pattern is
low because this study includes a low numbers of pa-
tients.
In conclusion, we identified several proteins that
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might play roles in the development of pathologic dif-
ferences between UIP and fNSIP patterns in chronic
HP. Further studies are warranted to clarify the role
of these proteins in the development of pulmonary fi-
brosis in chronic HP.
ACKNOWLEDGEMENTS
The authors wish to thank Takeshi Kasama, Instru-
mental Analysis Research Center for Life Science at
Tokyo Medical and Dental University and Makiko
Nawa, Laboratory of Cytometry and Proteome Re-
search at Tokyo Medical and Dental University, for
their help with mass spectrum analysis, and we also
thank Dr. Tamiko Takemura, Department of Pathol-
ogy, Japan Red Cross Center and Dr. Takumi Akashi,
the Department of Pathology at Tokyo Medical and
Dental University, for discussions on histopathology.
REFERENCES
1. Fink JN. Hypersensitivity pneumonitis. J Allergy Clin Im-
munol 1984;74:1-10.
2. Lacasse Y, Selman M, Costabel U et al. Classification of
hypersensitivity pneumonitis: a hypothesis. Int Arch Al-
lergy Immunol 2009;149:161-6.
3. Ohtani Y, Saiki S, Sumi Y et al. Clinical features of recur-
rent and insidious chronic bird fancier’s lung. Ann Allergy
Asthma Immunol 2003;90:604-10.
4. Ohtani Y, Saiki S, Kitaichi M et al. Chronic bird fancier’s
lung: histopathological and clinical correlation. An appli-
cation of the 2002 ATSERS consensus classification of
the idiopathic interstitial pneumonias. Thorax 2005;60:
665-71.
5. American Thoracic Society. Idiopathic pulmonary fibro-
sis: diagnosis and treatment. International consensus
statement. American Thoracic Society (ATS), and the
European Respiratory Society (ERS). Am J Respir Crit
Care Med 2000;161:646-64.
6. Yang I, Burch L, Steele M et al. Gene expression profiling
of familial and sporadic interstitial pneumonia. Am J
Respir Crit Care Med 2007;175:45-54.
7. Miyazaki Y, Tateishi T, Akashi T, Ohtani Y, Inase N,
Yoshizawa Y. Clinical predictors and histologic appear-
ance of acute exacerbations in chronic hypersensitivity
pneumonitis. Chest 2008;134:1265-70.
8. Wattiez R, Hermans C, Cruyt C, Bernard A, Falmagne P.
Human bronchoalveolar lavage fluid protein two-
dimensional database: study of interstitial lung diseases.
Electrophoresis 2000;21:2703-12.
9. Kim T, Lee Y, Kim K et al. Role of lung apolipoprotein A-I
in idiopathic pulmonary fibrosis: antiinflammatory and an-
tifibrotic effect on experimental lung injury and fibrosis.
Am J Respir Crit Care Med 2010;182:633-42.
10. He C. Proteomic analysis of human bronchoalveolar lav-
age fluid: expression profiling of surfactant-associated
protein A isomers derived from human pulmonary alveo-
lar proteinosis using immunoaffinity detection. Proteomics
2003;3:87-94.
11. Doyle I, Davidson K, Barr H, Nicholas T, Payne K,
Pfitzner J. Quantity and structure of surfactant proteins
vary among patients with alveolar proteinosis. Am J Respir
Crit Care Med 1998;157:658-64.
12. Bai Y, Galetskiy D, Damoc E et al. High resolution mass
spectrometric alveolar proteomics: identification of surfac-
tant protein SP-A and SP-D modifications in proteinosis
and cystic fibrosis patients. Proteomics 2004;4:2300-9.
13. Ohlmeier S, Vuolanto M, Toljamo T et al. Proteomics of
human lung tissue identifies surfactant protein A as a
marker of chronic obstructive pulmonary disease. J Pro-
teome Res 2008;7:5125-32.
14. Fietta A, Bardoni A, Salvini R et al. Analysis of bronchoal-
veolar lavage fluid proteome from systemic sclerosis pa-
tients with or without functional, clinical and radiological
signs of lung fibrosis. Arthritis Res Ther 2006;8:R160.
15. Reynolds HY. Bronchoalveolar lavage. Am Rev Respir Dis
1987;135:250-63.
16. Kishi M, Miyazaki Y, Jinta T et al. Pathogenesis of cBFL
in common with IPF? Correlation of IP-10TARC ratio
with histological patterns. Thorax 2008;63:810-6.
17. Shirahama R, Miyazaki Y, Okamoto T, Inase N, Yoshi-
zawa Y. Proteome analysis of bronchoalveolar lavage fluid
in lung fibrosis associated with systemic sclerosis. Aller-
gol Int 2010;59:409-15.
18. Wattiez R, Falmagne P. Proteomics of bronchoalveolar
lavage fluid. J Chromatogr B Analyt Technol Biomed Life
Sci 2005;815:169-78.
19. Vázquez de Lara L, Becerril C, Montaño M et al. Surfac-
tant components modulate fibroblast apoptosis and type I
collagen and collagenase-1 expression. Am J Physiol Lung
Cell Mol Physiol 2000;279:L950-7.
20. Phelps DS, Umstead TM, Mejia M, Carrillo G, Pardo A,
Selman M. Increased surfactant protein-A levels in pa-
tients with newly diagnosed idiopathic pulmonary fibro-
sis. Chest 2004;125:617-25.
21. McCormack FX, King TE, Voelker DR, Robinson PC, Ma-
son RJ. Idiopathic pulmonary fibrosis. Abnormalities in
the bronchoalveolar lavage content of surfactant protein
A. Am Rev Respir Dis 1991;144:160-6.
22. Günther A, Schmidt R, Nix F et al. Surfactant abnormali-
ties in idiopathic pulmonary fibrosis, hypersensitivity
pneumonitis and sarcoidosis. Eur Respir J 1999;14:565-73.
23. Boon K, Bailey NW, Yang J et al. Molecular phenotypes
distinguish patients with relatively stable from progres-
sive idiopathic pulmonary fibrosis (IPF). PLoS One 2009;
4:e5134.
24. Hamm H, Lührs J, Guzman y Rotaeche J, Costabel U, Fa-
bel H, Bartsch W. Elevated surfactant protein A in bron-
choalveolar lavage fluids from sarcoidosis and hypersen-
sitivity pneumonitis patients. Chest 1994;106:1766-70.
25. Madan T, Reid KB, Singh M, Sarma PU, Kishore U. Sus-
ceptibility of mice genetically deficient in the surfactant
protein (SP)-A or SP-D gene to pulmonary hypersensitiv-
ity induced by antigens and allergens of Aspergillus fumi-
gatus. J Immunol 2005;174:6943-54.
26. Morimoto RI, Santoro MG. Stress-inducible responses
and heat shock proteins: new pharmacologic targets for
cytoprotection. Nat Biotechnol 1998;16:833-8.
27. Fink AL. Chaperone-mediated protein folding. Physiol Rev
1999;79:425-49.
28. Xu Q, Schett G, Perschinka H et al. Serum soluble heat
shock protein 60 is elevated in subjects with atherosclero-
sis in a general population. Circulation 2000;102:14-20.
29. Feige U, Cohen IR. The 65-kDa heat-shock protein in the
pathogenesis, prevention and therapy of autoimmune ar-
thritis and diabetes mellitus in rats and mice. Springer
Semin Immunopathol 1991;13:99-113.
30. Baumann H, Jahreis GP, Morella KK. Interaction of
cytokine- and glucocorticoid-response elements of acute-
phase plasma protein genes. Importance of glucocorticoid
receptor level and cell type for regulation of the elements
Okamoto T et al.
92 Allergology International Vol 61, No1, 2012 www.jsaweb.jp
from rat alpha 1-acid glycoprotein and beta-fibrinogen
genes. J Biol Chem 1990;265:22275-81.
31. Yamamoto N, Homma S. Vitamin D3 binding protein
(group-specific component) is a precursor for the
macrophage-activating signal factor from lysophosphati-
dylcholine-treated lymphocytes. Proc Natl Acad Sci U S A
1991;88:8539-43.
32. Binder R, Kress A, Kan G, Herrmann K, Kirschfink M.
Neutrophil priming by cytokines and vitamin D binding
protein (Gc-globulin): impact on C5a-mediated chemo-
taxis, degranulation and respiratory burst. Mol Immunol
1999;36:885-92.
33. Haddad JG, Hu YZ, Kowalski MA et al. Identification of
the sterol- and actin-binding domains of plasma vitamin D
binding protein (Gc-globulin). Biochemistry 1992;31:7174-
81.
34. Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG.
Oxidant-mediated epithelial cell injury in idiopathic pul-
monary fibrosis. J Clin Invest 1987;79:1665-73.
35. Demedts M, Behr J, Buhl R et al. High-dose acetylcyste-
ine in idiopathic pulmonary fibrosis. N Engl J Med 2005;
353:2229-42.
